This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express a constitutively active IL7 receptor (C7R) and a chimeric antigen receptor (CAR) for CD30 (C7R.CD30-CAR-EBVSTs) in patients with relapsed or refractory CD30-positive lymphomas.
Participants who meet procurement eligibility criteria will undergo collection of peripheral blood mononuclear cells for manufacture of the investigational product. Participants with a successfully manufactured product who continue to meet treatment eligibility criteria will receive lymphodepleting chemotherapy followed by infusion of autologous C7R.CD30-CAR-EBVSTs.
The primary objective is to evaluate safety. Secondary and exploratory objectives include evaluation of antitumor effect, expansion and persistence of the infused cells, and the association between immunological parameters, safety, and clinical response.
Diagnosis of relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma.
CD30 positive tumor (can be pending at this time) as assayed in a CLIA certified Pathology Laboratory.
Age 16 to 75 years.
Hemoglobin ≥7.0(may be transfused value).
Active HIV or HTLV infection (testing may be pending at procurement).
Active bacterial, fungal, or viral infection.
Hodgkin lymphoma
CD30+ aggressive B-cell lymphoma
The Methodist Hospital Research Institute
Lead sponsor
Baylor College of Medicine
Collaborator